Findings in favor of treating COVID-19 infections with hydroxychloroquine (HCQ) + azithromycin (AZM)
Research indicating positive outcomes for treating COVID-19 with a combination of hydroxychloroquine (HCQ) and azithromycin (AZM) includes:
- A French open-label clinical trial showing increased viral clearance by day 6.
- In vitro testing demonstrating a synergistic antiviral effect against SARS-CoV-2.
- A retrospective Detroit study (Henry Ford Medical Group) finding the treatment effective when administered aggressively within 48 hours of patient admission.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Findings opposed to use of Azithromycin+Hydroxychloroquine as COVID-19 intervention
Findings in favor of treating COVID-19 infections with hydroxychloroquine (HCQ) + azithromycin (AZM)
Findings indicating no significant difference for treating COVID-19 infections with hydroxychloroquine (HCQ) + azithromycin (AZM)
Learn After
In a French open-label non-randomized clinical trial, more patients treated with hydroxychloroquine+azithromycin tested negative for COVID-19 by day 6 after inclusion in study compared to a control group
In vitro testing revealed synergistic effect of combined hydroxychloroquine (HCQ) and azithromycin (AZM) on SARS-CoV-2
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19